Price$4.72-0.89 (-15.86%)
2026-03-092026-06-10
News · 26 weeks55-67%
2025-12-142026-06-07
Mix2190d
- Other8(38%)
- SEC Filings8(38%)
- Insider3(14%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- INSIDERDirector Satter Muneer A bought $3,319,019 worth of shares (613,497 units at $5.41) (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- PRAnnexon to Participate in Upcoming June Investor ConferencesBRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences: Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and, Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET in Miami Beach, FL. Live webcasts of the presentations can be accessed u
- PRAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new non-executive employees received options to purchase 243,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal t
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)
- INSIDERDirector Carson William H. bought $46,240 worth of shares (8,000 units at $5.78), increasing direct ownership by 11% to 78,405 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- ANALYSTGoldman initiated coverage on Annexon with a new price targetGoldman initiated coverage of Annexon with a rating of Neutral and set a new price target of $7.00
- SECSEC Form 10-Q filed by Annexon Inc.10-Q - Annexon, Inc. (0001528115) (Filer)
- SECAnnexon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Annexon, Inc. (0001528115) (Filer)
- PRAnnexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated MilestonesTopline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA) Under Review as the Potentially First Targeted Therapy for Guillain-Barré Syndrome (GBS); Biologics License Application (BLA) Submission with U.S./European FORWARD Data Expected in 2026 Proof-of-Concept (POC) Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $225 Million as of March 31, 2026, and Anticipated Runway into Second Half 2027 B
- PRAnnexon to Present at the Bank of America Securities Health Care Conference 2026BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., President and Chief Executive Officer, will present at the Bank of America Securities Health Care Conference 2026 on Wednesday, May 13, 2026 at 11:20 a.m. PT. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. A
- SECSEC Form DEFA14A filed by Annexon Inc.DEFA14A - Annexon, Inc. (0001528115) (Filer)
- SECSEC Form DEF 14A filed by Annexon Inc.DEF 14A - Annexon, Inc. (0001528115) (Filer)
- SECSEC Form PRE 14A filed by Annexon Inc.PRE 14A - Annexon, Inc. (0001528115) (Filer)
- INSIDERSEC Form 4 filed by Carson William H.4 - Annexon, Inc. (0001528115) (Issuer)
- PRAnnexon to Present at the 25th Annual Needham Virtual Healthcare ConferenceBRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Ab
- SECSEC Form S-3ASR filed by Annexon Inc.S-3ASR - Annexon, Inc. (0001528115) (Filer)
- SECSEC Form 10-K filed by Annexon Inc.10-K - Annexon, Inc. (0001528115) (Filer)
- SECAnnexon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Annexon, Inc. (0001528115) (Filer)
- PRAnnexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); U.S./European FORWARD Study Data Expected to Support Planned BLA Submission in 2026 ANX1502 Advancing as First Oral C1 Inhibitor for Autoimmune Disease; Proof-of-Concept (POC) Data Anticipated in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $238.3 Million as of December 31, 2025, and Anticipated Runway into Second Half 2027 BRISBANE, Calif., March 30,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)
- PRAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-executive employee received an option to purchase 20,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $5.66, which was t
- INSIDERDirector Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF SCIENTIFIC OFFICER Artis Dean Richard sold $32,004 worth of shares (5,894 units at $5.43), decreasing direct ownership by 3% to 180,093 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF FINANCIAL OFFICER Lew Jennifer sold $30,162 worth of shares (5,565 units at $5.42), decreasing direct ownership by 3% to 170,700 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF BUSINESS OFFICER Overdorf Michael sold $23,517 worth of shares (4,339 units at $5.42), decreasing direct ownership by 2% to 182,625 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
ANNX FAQ
7 questionsWhat does Annexon Inc. do?
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical...Where does ANNX stock trade?
Annexon Inc. (ANNX) is listed on NASDAQ.What sector and industry is ANNX in?
Annexon Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Annexon Inc. go public?
Annexon Inc. (ANNX) completed its IPO in 2020.What are analysts saying about ANNX?
Annexon Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $700.00 price target on 2026-05-12.What companies are similar to ANNX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ANNX side-by-side with any of them on Quantisnow.How can I track ANNX on Quantisnow?
Quantisnow aggregates Annexon Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANNX to receive live email and push alerts on every new disclosure.